Physician profile
Erwin J Oei
NPI 1659373421
$4,328.80
in general payments reported to CMS, 2019-2025
28 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $186 · 2021: $68.30 · 2022: $158 · 2023: $494 · 2024: $982 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,072 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,072.23 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,480.05 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,127.17 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.88 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $238.19 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $145.96 | 2023-2025 | Dupixent |
| Grifols USA, LLC | $142.30 | 2022-2025 | Prolastin-C Liquid |
| Amgen INC. | $128.94 | 2019-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $106.35 | 2023-2025 | Glassia, Eohilia, Aralast |
| Viatris Specialty LLC | $91.77 | 2025 | Yupelri |
| Mylan Specialty L.P. | $90.74 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $71.76 | 2019-2020 | |
| Verona Pharma, INC. | $53.95 | 2025 | Ohtuvayre |
| Optinose US, INC. | $52.48 | 2019-2024 | |
| Insmed, INC. | $45.90 | 2019-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $42.48 | 2019-2023 | Verquvo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $34.85 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Monarch Airway Clearance System |
| Pfizer INC. | $27.66 | 2022-2024 | |
| Circassia INC. | $25.10 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $18.11 | 2025 | Lumryz |
| Bayer Healthcare Pharmaceuticals INC. | $17.95 | 2025 | |
| Axsome Therapeutics, INC. | $16.35 | 2025 | Sunosi |
| Philips North America LLC | $15.12 | 2025 | Vest Therapy Und |
| Lilly USA, LLC | $14.64 | 2019 | |
| Electromed, INC. | $14.31 | 2025 | Smartvest |
| Advanced Respiratory, INC | $13.89 | 2019 | |
| Mallinckrodt Hospital Products INC. | $12.25 | 2020 | |
| Mallinckrodt Enterprises LLC | $11.40 | 2019 | |
| Amarin Pharma, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erwin Oei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.